AM
The startup develops protein degradation drugs using an AI-enabled platform to identify and target disease-related proteins in cancer, neurodegenerative, and aging-related diseases. This approach provides researchers and pharmaceutical companies with a new class of therapeutics that can overcome drug resistance in life-threatening conditions.
Updated 4 months ago
Funding
$10M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Features
- The startup develops protein degradation drugs using an AI-enabled platform to identify and target disease-related proteins in cancer, neurodegenerative, and aging-related diseases. This approach provides researchers and pharmaceutical companies with a new class of therapeutics that can overcome drug resistance in life-threatening conditions.